Related Experiment Video
Updated: Jul 2, 2026

Evaluation of the Efficacy And Toxicity of RNAs Targeting HIV-1 Production for Use in Gene or Drug Therapy
Published on: September 5, 2016
[Inhibitory effect of RNAi targeting human telomerase reverse transcriptase against human hepatocellular carcinoma
Hua Li1, Xin-lu Wang, Yang Yang
1Liver Transplantation Center, Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China. lihua100@yeah.net
Objective:
To construct a recombinant retrovirus vector expressing small interfering RNA (siRNA) targeting human telomerase reverse transcriptase (hTERT), and assess its effect on proliferation and apoptosis of human hepatocellular carcinoma cells.
Methods:
The sequence of the siRNA targeting hTERT, U6 promoter and EGFP gene were amplified by PCR and inserted into the mammalian retroviral expression vector pLXSN to construct the recombinant retroviral vector pLXSN-EGFP-U6-siTERT. The vector was then used to infect human hepatocellular carcinoma cell HepG2. The telomerase activity of the infected cells was detected by telomerase repeat amplification protocol-silver staining, and the cell apoptosis was examined using flow cytometry. The inhibition rate of HepG2 cell proliferation was analyzed by MTT assay.
Results:
Sequence analysis and restriction enzyme digestion showed confirmed successful construction of the recombinant expression vector pLXSN-EGFP-U6-siTERT. The telomerase activity of the infected HepG2 cells was reduced by 23.84%, 58.03% and 85.01% at 24, 48 and 72 h after the infection, respectively (P<0.05). The cell apoptosis rate of the infected cells was 29.05% at 24 h after the infection. The cell proliferation was markedly inhibited by the infection with the vector in comparison to that of the control group.
Conclusion:
hTERT siRNA can effectively silence hTERT gene and suppress the telomerase activity and proliferation of HepG2 cells.
Insights
This study demonstrates that small interfering RNA (siRNA) targeting human telomerase reverse transcriptase (hTERT) effectively suppresses hepatocellular carcinoma cell proliferation and activity. The developed retroviral vector successfully reduced telomerase activity and induced apoptosis in HepG2 cells.
Area of Science:
- Molecular Biology
- Cancer Research
- Gene Therapy
Context:
- Hepatocellular carcinoma (HCC) is a significant global health concern with limited treatment options.
- Human telomerase reverse transcriptase (hTERT) is a key enzyme in telomere maintenance, often overexpressed in cancer cells, contributing to uncontrolled proliferation.
- Targeting hTERT presents a promising strategy for inhibiting cancer cell growth and inducing apoptosis.
Purpose:
- To construct a recombinant retroviral vector (pLXSN-EGFP-U6-siTERT) for delivering small interfering RNA (siRNA) against hTERT.
- To evaluate the efficacy of this vector in inhibiting telomerase activity, inducing apoptosis, and suppressing proliferation in human hepatocellular carcinoma (HepG2) cells.
Summary:
- The recombinant retroviral vector pLXSN-EGFP-U6-siTERT was successfully constructed and sequence-verified.
- Infection of HepG2 cells with the vector led to significant reductions in telomerase activity (up to 85.01% at 72 hours) and a notable increase in apoptosis rate (29.05% at 24 hours).
- MTT assays confirmed marked inhibition of HepG2 cell proliferation compared to control groups.
Impact:
- This research validates the potential of hTERT siRNA delivered via a retroviral vector as a therapeutic strategy for hepatocellular carcinoma.
- The findings suggest that silencing hTERT can effectively control cancer cell proliferation and promote cell death, offering a new avenue for HCC treatment.
- Further investigation into this gene-silencing approach could lead to novel targeted therapies for various cancers characterized by hTERT overexpression.
More Related Videos
Related Concept Videos
Experimental RNAi
RNA Interference
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
RNA Interference
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
lncRNA - Long Non-coding RNAs
Replicative Cell Senescence
siRNA - Small Interfering RNAs
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the ATP-dependent...

